John Farrell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
John Farrell has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
- Munir Pirmohamed
University of Liverpool Department of Pharmacology and Therapeutics
22 shared publications B. Kevin Park
MRC Center for Drug Safety Science, Department of Molecular and Clinical Pharmacology, The University of Liverpool, Liverpool, United Kingdom
21 shared publications- Dean John Naisbitt
University of Liverpool
16 shared publications Dean J. Naisbitt
MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology bDepartment of Chemistry, University of Liverpool, Liverpool, England cLaboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland, USA dDrug Metabolism and Pharmacokinetics, GlaxoSmithKline, Hertfordshire, England
13 shared publicationsSidonie N. Lavergne
7 shared publicationsDaniel Peckham
St James's Hospital, Regional Adult Cystic Fibrosis Unit, UK
6 shared publications
Latest Publications
- 11 June 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-3
Characterizing TeO2 Formation in CdTe Devices Using Transmission Electron Microscopy
Poly-crystalline CdTe/Cd(Se)Te based thin film solar cells have shown to be competitive in terms of efficiency and cost of electricity production. Yet, the presence of hetero-interfaces in Cd(Se)Te structure and low minority carrier lifetime have limited the thin film devices from reaching their maximum theoretical efficiency of approximately 30 percent. The back-contact of CdSeTe devices has been identified as one significant limitation to increased device performance since no metal has been identified that has a sufficiently high work function to create an Ohmic contact with the CdTe absorber at the back-surface of the film stack. Here, we will explore the formation of native TeO 2 on the back contact of solar cells to draw inferences on device performance. Atomic-resolution imaging in a scanning transmission electron microscope (STEM) combined with electron energy-loss spectroscopy (EELS) are used to characterize these devices and to inform the production process. The goal is to identify the mechanisms of TeO 2 formation and its role in passivating the back contact.
- 11 June 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-3
Characterizing TeO2 Formation in CdTe Devices Using Transmission Electron Microscopy
Poly-crystalline CdTe/Cd(Se)Te based thin film solar cells have shown to be competitive in terms of efficiency and cost of electricity production. Yet, the presence of hetero-interfaces in Cd(Se)Te structure and low minority carrier lifetime have limited the thin film devices from reaching their maximum theoretical efficiency of approximately 30 percent. The back-contact of CdSeTe devices has been identified as one significant limitation to increased device performance since no metal has been identified that has a sufficiently high work function to create an Ohmic contact with the CdTe absorber at the back-surface of the film stack. Here, we will explore the formation of native TeO 2 on the back contact of solar cells to draw inferences on device performance. Atomic-resolution imaging in a scanning transmission electron microscope (STEM) combined with electron energy-loss spectroscopy (EELS) are used to characterize these devices and to inform the production process. The goal is to identify the mechanisms of TeO 2 formation and its role in passivating the back contact.
- Open Access
Detection of drug‐responsive B lymphocytes and antidrug IgG in patients with β‐lactam hypersensitivity
Background Delayed‐type β‐lactam hypersensitivity develops in subset of patients. The cellular immunological processes that underlie the drug‐specific response have been described; however, little is known about involvement of the humoral immune system. Thus, the aim of this study was to utilize piperacillin hypersensitivity as an exemplar to (i) develop cell culture methods for the detection of drug‐specific B‐cell responses, (ii) characterize drug‐specific IgG subtypes and (iii) assess reactivity of IgG antibodies against proteins modified to different levels with piperacillin haptens. Methods IgG secretion and CD19+CD27+ expression on B cells were measured using ELISPOT and flow cytometry, respectively. A piperacillin–BSA adduct was used as an antigen in ELISA antibody binding studies. Adducts generated using different ratios of drug to protein were used to determine the degree of conjugation required to detect IgG binding. Results B cells from hypersensitive patients, but not controls, were stimulated to secrete IgG and increase CD27 expression when cultured with soluble piperacillin. A piperacillin–BSA adduct with cyclized and hydrolysed forms of the hapten bound to eight lysine residues was used to detect hapten‐specific IgG 1‐4 subclasses in patient plasma. Hapten inhibition and the use of structurally unrelated hapten–BSA adducts confirmed antigen specificity. Antibody binding was detected with antigens generated at piperacillin/BSA ratios of 10:1 and above, which corresponded to a minimum epitope density of 1 for antibody binding. Conclusion These data show that antigen‐specific B lymphocytes and T lymphocytes are activated in piperacillin‐hypersensitive patients. Further work is needed to define the role different IgG subtypes play in regulating the iatrogenic disease.
Open AccessDetection of drug‐responsive B lymphocytes and antidrug IgG in patients with β‐lactam hypersensitivity
Background Delayed‐type β‐lactam hypersensitivity develops in subset of patients. The cellular immunological processes that underlie the drug‐specific response have been described; however, little is known about involvement of the humoral immune system. Thus, the aim of this study was to utilize piperacillin hypersensitivity as an exemplar to (i) develop cell culture methods for the detection of drug‐specific B‐cell responses, (ii) characterize drug‐specific IgG subtypes and (iii) assess reactivity of IgG antibodies against proteins modified to different levels with piperacillin haptens. Methods IgG secretion and CD19+CD27+ expression on B cells were measured using ELISPOT and flow cytometry, respectively. A piperacillin–BSA adduct was used as an antigen in ELISA antibody binding studies. Adducts generated using different ratios of drug to protein were used to determine the degree of conjugation required to detect IgG binding. Results B cells from hypersensitive patients, but not controls, were stimulated to secrete IgG and increase CD27 expression when cultured with soluble piperacillin. A piperacillin–BSA adduct with cyclized and hydrolysed forms of the hapten bound to eight lysine residues was used to detect hapten‐specific IgG 1‐4 subclasses in patient plasma. Hapten inhibition and the use of structurally unrelated hapten–BSA adducts confirmed antigen specificity. Antibody binding was detected with antigens generated at piperacillin/BSA ratios of 10:1 and above, which corresponded to a minimum epitope density of 1 for antibody binding. Conclusion These data show that antigen‐specific B lymphocytes and T lymphocytes are activated in piperacillin‐hypersensitive patients. Further work is needed to define the role different IgG subtypes play in regulating the iatrogenic disease.
- 28 November 2015
- Published by Wolters Kluwer Health in AIDS
- Vol. 29 (18) , 2385-2395
Towards depersonalized abacavir therapy
Exposure to abacavir is associated with T-cell-mediated hypersensitivity reactions in individuals carrying human leukocyte antigen (HLA)-B*57 : 01. To activate T cells, abacavir interacts directly with endogenous HLA-B*57 : 01 and HLA-B*57 : 01 expressed on the surface of antigen presenting cells. We have investigated whether chemical modification of abacavir can produce a molecule with antiviral activity that does not bind to HLA-B*57 : 01 and activate T cells. An interdisciplinary laboratory study using samples from human donors expressing HLA-B*57 : 01. Researchers were blinded to the analogue structures and modelling data. Sixteen 6-amino substituted abacavir analogues were synthesized. Computational docking studies were completed to predict capacity for analogue binding within HLA-B*57 : 01. Abacavir-responsive CD8+ clones were generated to study the association between HLA-B*57 : 01 analogue binding and T-cell activation. Antiviral activity and the direct inhibitory effect of analogues on proliferation were assessed. Major histocompatibility complex class I-restricted CD8+ clones proliferated and secreted IFNγ following abacavir binding to surface and endogenous HLA-B*57 : 01. Several analogues retained antiviral activity and showed no overt inhibitory effect on proliferation, but displayed highly divergent antigen-driven T-cell responses. For example, abacavir and N-propyl abacavir were equally potent at activating clones, whereas the closely related analogues N-isopropyl and N-methyl isopropyl abacavir were devoid of T-cell activity. Docking abacavir analogues to HLA-B*57 : 01 revealed a quantitative relationship between drug–protein binding and the T-cell response. These studies demonstrate that the unwanted T-cell activity of abacavir can be eliminated whilst maintaining the favourable antiviral profile. The in-silico model provides a tool to aid the design of safer antiviral agents that may not require a personalized medicines approach to therapy.
- 28 November 2015
- Published by Wolters Kluwer Health in AIDS
- Vol. 29 (18) , 2385-2395
Towards depersonalized abacavir therapy
Exposure to abacavir is associated with T-cell-mediated hypersensitivity reactions in individuals carrying human leukocyte antigen (HLA)-B*57 : 01. To activate T cells, abacavir interacts directly with endogenous HLA-B*57 : 01 and HLA-B*57 : 01 expressed on the surface of antigen presenting cells. We have investigated whether chemical modification of abacavir can produce a molecule with antiviral activity that does not bind to HLA-B*57 : 01 and activate T cells. An interdisciplinary laboratory study using samples from human donors expressing HLA-B*57 : 01. Researchers were blinded to the analogue structures and modelling data. Sixteen 6-amino substituted abacavir analogues were synthesized. Computational docking studies were completed to predict capacity for analogue binding within HLA-B*57 : 01. Abacavir-responsive CD8+ clones were generated to study the association between HLA-B*57 : 01 analogue binding and T-cell activation. Antiviral activity and the direct inhibitory effect of analogues on proliferation were assessed. Major histocompatibility complex class I-restricted CD8+ clones proliferated and secreted IFNγ following abacavir binding to surface and endogenous HLA-B*57 : 01. Several analogues retained antiviral activity and showed no overt inhibitory effect on proliferation, but displayed highly divergent antigen-driven T-cell responses. For example, abacavir and N-propyl abacavir were equally potent at activating clones, whereas the closely related analogues N-isopropyl and N-methyl isopropyl abacavir were devoid of T-cell activity. Docking abacavir analogues to HLA-B*57 : 01 revealed a quantitative relationship between drug–protein binding and the T-cell response. These studies demonstrate that the unwanted T-cell activity of abacavir can be eliminated whilst maintaining the favourable antiviral profile. The in-silico model provides a tool to aid the design of safer antiviral agents that may not require a personalized medicines approach to therapy.
- Open Access
- 22 May 2015
- Published by Wolters Kluwer Health in Hepatology
- Vol. 62 (3) , 887-899
Characterization of amoxicillin‐ and clavulanic acid‐specific T cells in patients with amoxicillin‐clavulanate–induced liver injury
Drug‐induced liver injury (DILI) frequently has a delayed onset with several human leukocyte antigen (HLA) genotypes affecting susceptibility, indicating a potential role for the adaptive immune system in the disease. The aim of this study was to investigate whether drug‐responsive T lymphocytes are detectable in patients who developed DILI with the combination, antimicrobial amoxicillin‐clavulanate. Lymphocytes from 6 of 7 patients were found to proliferate and/or secrete interferon‐gamma (IFN‐γ) when cultured with amoxicillin and/or clavulanic acid. Amoxicillin (n = 105) and clavulanic acid (n = 16) responsive CD4+ and CD8+ T‐cell clones expressing CCR, chemokine (C‐C motif) receptor 4, CCR9, and chemokine (C‐X‐C motif) receptor 3 were generated from patients with and without HLA risk alleles; no cross‐reactivity was observed between the two drug antigens. Amoxicillin clones were found to secrete a heterogeneous panel of mediators, including IFN‐γ, interleukin‐22 and cytolytic molecules. In contrast, cytokine secretion by the clavulanic acid clones was more restricted. CD4+ and CD8+ clones were major histocompatability complex class II and I restricted, respectively, with the drug antigen being presented to CD4+ clones in the context of HLA‐DR molecules. Several pieces of evidence indicate that the clones were activated by a hapten mechanism: First, professional antigen‐presenting cells (APCs) were required for optimal activation; second, pulsing APCs for 4‐16 hours activated the clones; and third, inhibition of processing abrogated the proliferative response and cytokine release. Conclusion: Both amoxicillin‐ and clavulanic acid–specific T cells participate in the liver injury that develops in certain patients exposed to amoxicillin‐clavulanate. (Hepatology 2015;62:887‐899)
- 22 May 2015
- Published by Wolters Kluwer Health in Hepatology
- Vol. 62 (3) , 887-899
Open AccessCharacterization of amoxicillin‐ and clavulanic acid‐specific T cells in patients with amoxicillin‐clavulanate–induced liver injury
Drug‐induced liver injury (DILI) frequently has a delayed onset with several human leukocyte antigen (HLA) genotypes affecting susceptibility, indicating a potential role for the adaptive immune system in the disease. The aim of this study was to investigate whether drug‐responsive T lymphocytes are detectable in patients who developed DILI with the combination, antimicrobial amoxicillin‐clavulanate. Lymphocytes from 6 of 7 patients were found to proliferate and/or secrete interferon‐gamma (IFN‐γ) when cultured with amoxicillin and/or clavulanic acid. Amoxicillin (n = 105) and clavulanic acid (n = 16) responsive CD4+ and CD8+ T‐cell clones expressing CCR, chemokine (C‐C motif) receptor 4, CCR9, and chemokine (C‐X‐C motif) receptor 3 were generated from patients with and without HLA risk alleles; no cross‐reactivity was observed between the two drug antigens. Amoxicillin clones were found to secrete a heterogeneous panel of mediators, including IFN‐γ, interleukin‐22 and cytolytic molecules. In contrast, cytokine secretion by the clavulanic acid clones was more restricted. CD4+ and CD8+ clones were major histocompatability complex class II and I restricted, respectively, with the drug antigen being presented to CD4+ clones in the context of HLA‐DR molecules. Several pieces of evidence indicate that the clones were activated by a hapten mechanism: First, professional antigen‐presenting cells (APCs) were required for optimal activation; second, pulsing APCs for 4‐16 hours activated the clones; and third, inhibition of processing abrogated the proliferative response and cytokine release. Conclusion: Both amoxicillin‐ and clavulanic acid–specific T cells participate in the liver injury that develops in certain patients exposed to amoxicillin‐clavulanate. (Hepatology 2015;62:887‐899)
- Open Access
- 1 May 2015
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 21 (5) , 914-916
Enterovirus D68–Associated Acute Respiratory Distress Syndrome in Adult, United States, 2014
- 1 May 2015
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 21 (5) , 914-916
Open AccessEnterovirus D68–Associated Acute Respiratory Distress Syndrome in Adult, United States, 2014
- 25 February 2015
- Published by Wiley in European journal of pain
- Vol. 19 (10) , 1516-1526
Cutaneous immunopathology of long‐standing complex regional pain syndrome
Background: Both increased mast cells numbers and raised immune mediator concentrations indicate immune activation in the affected skin of patients with early complex regional pain syndrome (CRPS), but little is known about regional immune cell involvement in late‐stage CRPS. The aim of the current study was to determine skin immune cell populations in long‐standing CRPS.Methods: Using 6‐mm skin punch biopsies from CRPS‐affected and non‐affected tissues, and a combination of chemical and immunofluorescence staining, we examined the density and function of key cell populations including mast cells, epidermal Langerhans cells (LCs) and tissue resident T‐cells.Results: We found no significant differences in either overall immune cell infiltrates, or mast cell density between CRPS‐affected and non‐affected sub‐epidermal tissue sections, contrasting recent findings in early CRPS by other groups. However, CD1a+ LC densities in the epidermal layer were significantly decreased in affected compared to non‐affected CRPS limbs (p < 0.01). T‐cell clones isolated from CRPS‐affected sub‐epidermal tissues displayed a trend towards increased IL‐13 production in ELISPOT assays when compared to T‐cells isolated from non‐affected areas, suggesting a Th2 bias.Conclusions: Immune cell abnormalities are maintained in late‐stage CRPS disease as manifest by changes in epidermal LC density and tissue resident T‐cell phenotype.
- 25 February 2015
- Published by Wiley in European journal of pain
- Vol. 19 (10) , 1516-1526
Cutaneous immunopathology of long‐standing complex regional pain syndrome
Background: Both increased mast cells numbers and raised immune mediator concentrations indicate immune activation in the affected skin of patients with early complex regional pain syndrome (CRPS), but little is known about regional immune cell involvement in late‐stage CRPS. The aim of the current study was to determine skin immune cell populations in long‐standing CRPS.Methods: Using 6‐mm skin punch biopsies from CRPS‐affected and non‐affected tissues, and a combination of chemical and immunofluorescence staining, we examined the density and function of key cell populations including mast cells, epidermal Langerhans cells (LCs) and tissue resident T‐cells.Results: We found no significant differences in either overall immune cell infiltrates, or mast cell density between CRPS‐affected and non‐affected sub‐epidermal tissue sections, contrasting recent findings in early CRPS by other groups. However, CD1a+ LC densities in the epidermal layer were significantly decreased in affected compared to non‐affected CRPS limbs (p < 0.01). T‐cell clones isolated from CRPS‐affected sub‐epidermal tissues displayed a trend towards increased IL‐13 production in ELISPOT assays when compared to T‐cells isolated from non‐affected areas, suggesting a Th2 bias.Conclusions: Immune cell abnormalities are maintained in late‐stage CRPS disease as manifest by changes in epidermal LC density and tissue resident T‐cell phenotype.
- Open Access
- 18 July 2014
- Published by Wiley in Clinical and Translational Allergy
- Vol. 4 (S3) , P39
Characterization of the TCR V repertoire of piperacillin‐specific T‐cells
- 18 July 2014
- Published by Wiley in Clinical and Translational Allergy
- Vol. 4 (S3) , P39
Open AccessCharacterization of the TCR V repertoire of piperacillin‐specific T‐cells
- Open Access
- 18 July 2014
- Published by Wiley in Clinical and Translational Allergy
- Vol. 4 (S3) , P117
Abs No: HLA‐A*31:01 positive hypersensitive patient
- 18 July 2014
- Published by Wiley in Clinical and Translational Allergy
- Vol. 4 (S3) , P117
Open AccessAbs No: HLA‐A*31:01 positive hypersensitive patient
- Open Access
- 18 July 2014
- Published by Wiley in Clinical and Translational Allergy
- Vol. 4 (S3) , P113
Characterization of anti‐drug antibodies and drug‐responsive B‐lymphocytes in piperacillin hypersensitive patients with cystic fibrosis
- 18 July 2014
- Published by Wiley in Clinical and Translational Allergy
- Vol. 4 (S3) , P113
Open AccessCharacterization of anti‐drug antibodies and drug‐responsive B‐lymphocytes in piperacillin hypersensitive patients with cystic fibrosis
- Open Access
- 18 July 2014
- Published by Wiley in Clinical and Translational Allergy
- Vol. 4 (S3) , P108
Detection of interleukin‐22 secreting T‐cells in piperacillin hypersensitive patients with cystic fibrosis
- 18 July 2014
- Published by Wiley in Clinical and Translational Allergy
- Vol. 4 (S3) , P108
Open AccessDetection of interleukin‐22 secreting T‐cells in piperacillin hypersensitive patients with cystic fibrosis